Boston Scientific kept at strong buy by JMP

Boston Scientific Corp. was maintained at a strong buy rating by JMP Securities analyst Robert C. Faulkner on news that the company is temporarily halting supply of its new Xience V drug-eluting stent in international markets. A small number of stents were discovered to have been manufactured out of specification, and all inventory has been scrapped. International launch of the product is delayed to the third quarter of 2006, and enrollment in the Japanese and 4 mm arms of the Spirit 3 clinical trial are suspended. Shares of the Natick, Mass., medical device company were down 29 cents, or 1.23%, at $23.25 on volume of 8,931,900 shares versus the three-month running average of 10,178,700 shares. (NYSE: BSX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.